Literature DB >> 17456002

Why most published research findings are false: problems in the analysis.

Steven Goodman, Sander Greenland.   

Abstract

Mesh:

Year:  2007        PMID: 17456002      PMCID: PMC1855693          DOI: 10.1371/journal.pmed.0040168

Source DB:  PubMed          Journal:  PLoS Med        ISSN: 1549-1277            Impact factor:   11.069


× No keyword cloud information.
The article published in PLoS Medicine by Ioannidis [1] makes the dramatic claim in the title that “most published research claims are false,” and has received extensive attention as a result. The article does provide a useful reminder that the probability of hypotheses depends on much more than just the p-value, a point that has been made in the medical literature for at least four decades, and in the statistical literature for decades previous. This topic has renewed importance with the advent of the massive multiple testing often seen in genomics studies. Unfortunately, while we agree that there are more false claims than many would suspect—based both on poor study design, misinterpretation of p-values, and perhaps analytic manipulation—the mathematical argument in the PLoS Medicine paper underlying the “proof” of the title's claim has a degree of circularity. As we show in detail in a separately published paper [2], Dr. Ioannidis utilizes a mathematical model that severely diminishes the evidential value of studies—even meta-analyses—such that none can produce more than modest evidence against the null hypothesis, and most are far weaker. This is why, in the offered “proof,” the only study types that achieve a posterior probability of 50% or more (large RCTs [randomized controlled trials] and meta-analysis of RCTs) are those to which a prior probability of 50% or more are assigned. So the model employed cannot be considered a proof that most published claims are untrue, but is rather a claim that no study or combination of studies can ever provide convincing evidence. The two assumptions that produce the above effect are: Calculating the evidential effect only of verdicts of “significance,” i.e., p ≤ 0.05, instead of the actual p-value observed in a study, e.g., p = 0.001. Introducing a new “bias” term into the Bayesian calculations, which even at a described “minimal” level (of 10%) has the effect of very dramatically diminishing a study's evidential impact. In addition to the above problems, the paper claims to have proven something it describes as paradoxical; that the “hotter” an area is (i.e., the more studies published), the more likely studies in that area are to make false claims. We have shown this claim to be erroneous [2]. The mathematical proof offered for this in the PLoS Medicine paper shows merely that the more studies published on any subject, the higher the absolute number of false positive (and false negative) studies. It does not show what the papers' graphs and text claim, viz, that the number of false claims will be a higher proportion of the total number of studies published (i.e., that the positive predictive value of each study decreases with increasing number of studies). The paper offers useful guidance in a number of areas, calling attention to the importance of avoiding all forms of bias, of obtaining more empirical research on the prevalence of various forms of bias, and on the determinants of prior odds of hypotheses. But the claims that the model employed in this paper constitutes a “proof” that most published medical research claims are false, and that research in “hot” areas is most likely to be false, are unfounded.
  1 in total

1.  Why most published research findings are false.

Authors:  John P A Ioannidis
Journal:  PLoS Med       Date:  2005-08-30       Impact factor: 11.613

  1 in total
  17 in total

1.  Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison.

Authors:  Philip Mease; Ernest Choy; Peter Nash; Chrysostomos Kalyvas; Matthias Hunger; Luminita Pricop; Kunal K Gandhi; Steffen M Jugl; Howard Thom
Journal:  Eur J Rheumatol       Date:  2018-07-01

2.  False and true positives in arthropod thermal adaptation candidate gene lists.

Authors:  Maike Herrmann; Lev Y Yampolsky
Journal:  Genetica       Date:  2021-05-07       Impact factor: 1.082

3.  Transcriptional signatures of brain aging and Alzheimer's disease: What are our rodent models telling us?

Authors:  Kendra E Hargis; Eric M Blalock
Journal:  Behav Brain Res       Date:  2016-05-04       Impact factor: 3.332

4.  Cautionary Note on Using Cross-Validation for Molecular Classification.

Authors:  Li-Xuan Qin; Huei-Chung Huang; Colin B Begg
Journal:  J Clin Oncol       Date:  2016-11-10       Impact factor: 44.544

5.  A theory and methodology to quantify knowledge.

Authors:  Daniele Fanelli
Journal:  R Soc Open Sci       Date:  2019-04-03       Impact factor: 2.963

Review 6.  Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

7.  Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

Authors:  Peter Nash; Iain B McInnes; Philip J Mease; Howard Thom; Matthias Hunger; Andreas Karabis; Kunal Gandhi; Shephard Mpofu; Steffen M Jugl
Journal:  Rheumatol Ther       Date:  2018-03-31

Review 8.  Genomics and successful aging: grounds for renewed optimism?

Authors:  L C Pilling; L W Harries; J Powell; D J Llewellyn; L Ferrucci; D Melzer
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-27       Impact factor: 6.053

9.  The replication crisis in epidemiology: snowball, snow job, or winter solstice?

Authors:  Timothy L Lash; Lindsay J Collin; Miriam E Van Dyke
Journal:  Curr Epidemiol Rep       Date:  2018-04-12

10.  Why most published research findings are false: author's reply to Goodman and Greenland.

Authors:  John P A Ioannidis
Journal:  PLoS Med       Date:  2007-06       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.